144 related articles for article (PubMed ID: 20503316)
21. EEG improvements with antiepileptic drug treatment can show a high correlation with behavioral recovery in children with ADHD.
Kanemura H; Sano F; Tando T; Hosaka H; Sugita K; Aihara M
Epilepsy Behav; 2013 Jun; 27(3):443-8. PubMed ID: 23603034
[TBL] [Abstract][Full Text] [Related]
22. [Medical treatment of fragile X syndrome].
Artigas-Pallarés J; Brun-Gasca C
Rev Neurol; 2001 Oct; 33 Suppl 1():S41-50. PubMed ID: 12447819
[TBL] [Abstract][Full Text] [Related]
23. Effects of stimulus salience on touchscreen serial reversal learning in a mouse model of fragile X syndrome.
Dickson PE; Corkill B; McKimm E; Miller MM; Calton MA; Goldowitz D; Blaha CD; Mittleman G
Behav Brain Res; 2013 Sep; 252():126-35. PubMed ID: 23747611
[TBL] [Abstract][Full Text] [Related]
24. Effects of clonidine and methylphenidate on motor activity in Fmr1 knockout mice.
Wrenn CC; Heitzer AM; Roth AK; Nawrocki L; Valdovinos MG
Neurosci Lett; 2015 Jan; 585():109-13. PubMed ID: 25433180
[TBL] [Abstract][Full Text] [Related]
25. Reversion to Normal of
Tabolacci E; Pietrobono R; Maneri G; Remondini L; Nobile V; Della Monica M; Pomponi MG; Genuardi M; Neri G; Chiurazzi P
Genes (Basel); 2020 Feb; 11(3):. PubMed ID: 32111011
[TBL] [Abstract][Full Text] [Related]
26. Modeling fragile X syndrome in the Fmr1 knockout mouse.
Kazdoba TM; Leach PT; Silverman JL; Crawley JN
Intractable Rare Dis Res; 2014 Nov; 3(4):118-33. PubMed ID: 25606362
[TBL] [Abstract][Full Text] [Related]
27. The behavioral phenotype of FMR1 mutations.
Boyle L; Kaufmann WE
Am J Med Genet C Semin Med Genet; 2010 Nov; 154C(4):469-76. PubMed ID: 20981777
[TBL] [Abstract][Full Text] [Related]
28. The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro.
Tabolacci E; Pirozzi F; Gomez-Mancilla B; Gasparini F; Neri G
BMC Med Genet; 2012 Mar; 13():13. PubMed ID: 22397687
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.
Jacquemont S; Curie A; des Portes V; Torrioli MG; Berry-Kravis E; Hagerman RJ; Ramos FJ; Cornish K; He Y; Paulding C; Neri G; Chen F; Hadjikhani N; Martinet D; Meyer J; Beckmann JS; Delange K; Brun A; Bussy G; Gasparini F; Hilse T; Floesser A; Branson J; Bilbe G; Johns D; Gomez-Mancilla B
Sci Transl Med; 2011 Jan; 3(64):64ra1. PubMed ID: 21209411
[TBL] [Abstract][Full Text] [Related]
30. Deletion of the KH1 Domain of Fmr1 Leads to Transcriptional Alterations and Attentional Deficits in Rats.
Golden CEM; Breen MS; Koro L; Sonar S; Niblo K; Browne A; Burlant N; Di Marino D; De Rubeis S; Baxter MG; Buxbaum JD; Harony-Nicolas H
Cereb Cortex; 2019 May; 29(5):2228-2244. PubMed ID: 30877790
[TBL] [Abstract][Full Text] [Related]
31. Incomplete silencing of full mutation alleles in males with fragile X syndrome is associated with autistic features.
Baker EK; Arpone M; Aliaga SM; Bretherton L; Kraan CM; Bui M; Slater HR; Ling L; Francis D; Hunter MF; Elliott J; Rogers C; Field M; Cohen J; Cornish K; Santa Maria L; Faundes V; Curotto B; Morales P; Trigo C; Salas I; Alliende AM; Amor DJ; Godler DE
Mol Autism; 2019; 10():21. PubMed ID: 31073396
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of valproic acid treatment in SCA3/MJD patients.
Lei LF; Yang GP; Wang JL; Chuang DM; Song WH; Tang BS; Jiang H
Parkinsonism Relat Disord; 2016 May; 26():55-61. PubMed ID: 26997655
[TBL] [Abstract][Full Text] [Related]
33. Prenatal valproate exposure and adverse neurodevelopmental outcomes: Does sex matter?
Honybun E; Thwaites R; Malpas CB; Rayner G; Anderson A; Graham J; Hitchcock A; O'Brien TJ; Vajda FJE; Perucca P
Epilepsia; 2021 Mar; 62(3):709-719. PubMed ID: 33547648
[TBL] [Abstract][Full Text] [Related]
34. DNA Methylation, Mechanisms of
Nobile V; Pucci C; Chiurazzi P; Neri G; Tabolacci E
Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33669384
[TBL] [Abstract][Full Text] [Related]
35. CGG-repeat dynamics and
Zhou Y; Kumari D; Sciascia N; Usdin K
Mol Autism; 2016; 7():42. PubMed ID: 27713816
[TBL] [Abstract][Full Text] [Related]
36. Reactivation of FMR1 by CRISPR/Cas9-Mediated Deletion of the Expanded CGG-Repeat of the Fragile X Chromosome.
Xie N; Gong H; Suhl JA; Chopra P; Wang T; Warren ST
PLoS One; 2016; 11(10):e0165499. PubMed ID: 27768763
[TBL] [Abstract][Full Text] [Related]
37. FMR1 gene mutations in patients with fragile X syndrome and obligate carriers: 30 years of experience in Chile.
Santa María L; Aliaga S; Faundes V; Morales P; Pugin Á; Curotto B; Soto P; Peña MI; Salas I; Alliende MA
Genet Res (Camb); 2016 Jun; 98():e11. PubMed ID: 27350105
[TBL] [Abstract][Full Text] [Related]
38. A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome.
Heussler H; Cohen J; Silove N; Tich N; Bonn-Miller MO; Du W; O'Neill C; Sebree T
J Neurodev Disord; 2019 Aug; 11(1):16. PubMed ID: 31370779
[TBL] [Abstract][Full Text] [Related]
39. Activation of the extracellular signal-regulated kinase pathway contributes to the behavioral deficit of fragile x-syndrome.
Wang X; Snape M; Klann E; Stone JG; Singh A; Petersen RB; Castellani RJ; Casadesus G; Smith MA; Zhu X
J Neurochem; 2012 May; 121(4):672-9. PubMed ID: 22393900
[TBL] [Abstract][Full Text] [Related]
40. Point mutation frequency in the FMR1 gene as revealed by fragile X syndrome screening.
Handt M; Epplen A; Hoffjan S; Mese K; Epplen JT; Dekomien G
Mol Cell Probes; 2014; 28(5-6):279-83. PubMed ID: 25171808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
